Analysts: Buy This Biotech Stock Now

Raymond James thinks ZYME stock could double

Aug 2, 2018 at 1:41 PM
facebook twitter linkedin

The shares of biotech Zymeworks Inc (NYSE:ZYME) are higher today, thanks to some positive analyst attention. Last night -- and despite the stock's relatively blase reaction to earnings yesterday -- Raymond James reiterated its "outperform" rating and "high degree of conviction on the stock," saying it "strongly encourage[s] investors to take advantage of current valuation" ahead of upcoming clinical updates, including Zymeworks' R&D day in October. In addition, the analyst reiterated a $27 price target on ZYME -- in uncharted territory, and more than double the equity's current perch. Likewise, Citigroup this morning upgraded ZYME stock to "buy" from "neutral," and lifted its price target to $20. 

Zymeworks shares are now on pace to end atop their 10-day moving average, which has been guiding the equity lower since its June 1 all-time high of $26, touched after the company reported well-received data on ZW25 at the American Society of Clinical Oncology conference. What's more, $26 represents double ZYME's initial public offering (IPO) price of $13. At last check, ZYME was up 7.1% to trade at $13.29, set to snap a seven-day run south of its IPO price.

ZYME stock chart august 2

While the stock has surrendered nearly half its value since the June 1 peak, it's no stranger to upbeat analyst attention. Five of the seven analysts following ZYME already deem it worthy of a "buy" or better rating, and the consensus 12-month price target is a lofty $24.29 -- an 83% premium to current levels.


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!